
ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/115,589	<u> </u>
Source:	1647	
Date Processed by STIC:	6/30/2000	RECEIVED
	<del></del>	 JUL 28 2000

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

TECH CENTER 1600/2900

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR FURTHER INFORMATION, PLEASE TELEPHONE MARK SPENCER, 703-308-4212.

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

## Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2Kcompliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address: http://www.uspto.gov/web/offices/pac/checker

## Raw Sequence Listing Error Summary

SERIAL NUMBER:

## ERROR DETECTED SUGGESTED CORRECTION

The number/text at the end of each fine "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".  2	
Please adjust your right margin to .3, as this will prevent "wrapping".  The amino acid number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".  Incorrect Line Length  The rules require that a line not exceed 72 characters in length. This includes spaces.  The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.  This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  Patentin ver. 2.0 "bug"  Patentin ver. 2.0 "bug"  A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)	
The amino acid number/lext at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".  Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.  The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers. Please ensure your subsequent submission is saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. As per the rules, each nor Xaa can only represented more than one residue. As per the rules, each nor Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  TECH CENTER 1600/  Patentin ver. 2.0 "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)	
This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".  3 Incorrect Line Length	
Please adjust your right margin to 3, as this will prevent "wrapping".  The rules require that a line not exceed 72 characters in length. This includes spaces.  The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.  This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. Please ensure your subsequent submission is required by the Sequence Rules. As per the rules, each nor Xaa's which represented more than one residue. As per the rules, each nor Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  TECH CENTER 16000  The can be used to the use of tabs and use spacing between the numbers.  The rules required by the use of tabs between the numbers of each residue having variable length and indicate in the (ix) feature section that some may be missing.  The rules required by the sequence that can be processed.  The rules required by the use of tabs between the number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  The rules required by the Sequence than one residue.  The rules required by the sequence this manual processed.  The rules required by the sequence the number of each estidue having variable length and indicate in the (ix) feature section that some may be missing.  The rules required by the Sequence to the use of tabs.  The rules required by the Sequence than one residue.  The rules required by the Sequence was a required by the Sequence text of the use of tabs.  The rules required by the Sequence	
Incorrect Line Length  Misaligned Amino Acid Numbering  The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.  This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. Please present the maximum number of each residue. As per the rules, each nor Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  TECH CENTER 1600/  Patentin ver. 2.0 "bug"  A "bug" in Patentin version 2.0 has caused the <220> <223> section to be missing from amino acid sequence. Please manually copy the relevant <220> <223> section to the subsequent amino acid sequence. Please manually copy the relevant <220> <223> section to the subsequent amino acid sequence.  Skipped Sequences (OLD RULES)  (2) INFORMATION FOR SEQ ID NO:X: (3) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTIC (ix) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence. (10) sequence id number <100 se	
Misaligned Amino Acid Numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.  This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. As per the rules, each nor Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  TECH CENTER 1600/  A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)	
Numbering between the numbering. It is recommended to delete any tabs and use spacing between-the numbers.  Non-ASCII  This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed.  RECEIV  Variable Length  Sequence(s) contain n's or Xaa's which represented more than one residue. As per the rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  TECH CENTER 1600p  7 Patentin ver. 2.0 "bug"  A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  Sequence(s) missing. If intentional, please use the following format for each skipped sequence: (OLD RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES." response to include the skipped sequence(s).  Sequence(s) missing. If intentional, please use the following format for each skipped sequence (iii) NUMBER OF SEQUENCES." response to include the skipped sequence (s).  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  Please also adjust the "(iii) NUMBER OF SEQUENCES." response to include the skipped sequence (s).  Sequence(s) missing. If intentional, please use the following format for each skipped sequence (a) sequence id number (a) sequence (a) sequence (a) sequence (a) sequence (a	
Numbering between the numbering. It is recommended to delete any tabs and use spacing between the numbers.  Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed. The CETV Sequence(s) contain n's or Xaa's which represented more than one residue.  As per the rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  TECH CENTER 16000  Patentin ver. 2.0 "bug" A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  Skipped Sequences  (OLD RULES) Sequence(s) missing. If intentional, please use the following format for each skipped sequence:  (2) INFORMATION FOR SEQ ID NO:X:  (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTI (xi) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTI (xi) SEQUENCE CHARACTERISTICS:(Do not insert any headings to include the skipped sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES." response to include the skipped sequence (s).  Sequence(s) missing. If intentional, please use the following format for each skipped sequence (s).  Sequence id number 4000 sequence id number 4000 sequence id number 4000 sequence id number 4202 sequence id number	
Sequence(s) contain n's or Xaa's which represented more than one residue.  As per the rules, each n or Xaa can only represent a single residue, Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  7 Patentin ver. 2.0 "bug" A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  8 Skipped Sequences (OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:  (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTI (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  9 Skipped Sequences (NEW RULES) Sequence id number <400> sequence id number <400> sequence id number <400> sequence id number <400> sequence list number <400> sequence Listing.  Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.  Use of n's or Xaa's Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	-
Sequence(s) contain n's or Xaa's which represented more than one residue.  As per the rules, each n or Xaa can only represent a single residue, Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  7 Patentin ver. 2.0 "bug" A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  8 Skipped Sequences (OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:  (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTI (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  9 Skipped Sequences (NEW RULES) Sequence id number <400> sequence id number <400> sequence id number <400> sequence id number <400> sequence list number <400> sequence Listing.  Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.  Use of n's or Xaa's Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
Sequence(s) contain n's or Xaa's which represented more than one residue.  As per the rules, each n or Xaa can only represent a single residue, Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  7 Patentin ver. 2.0 "bug" A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  8 Skipped Sequences (OLD RULES) (2) INFORMATION FOR SEQ ID NO:X:  (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTI (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  9 Skipped Sequences (NEW RULES) Sequence id number <400> sequence id number <400> sequence id number <400> sequence id number <400> sequence list number <400> sequence Listing.  Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.  Use of n's or Xaa's Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
As per the rules, each n or Xaa can only represent a single residue.  Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  TECH CENTER 16000  Patentin ver. 2.0 "bug"  A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)	ED)
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.  7 — PatentIn ver. 2.0 "bug"  A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s)	
indicate in the (ix) feature section that some may be missing.  TECH CENTER 1600/  A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  Skipped Sequences (OLD RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence:  (2) INFORMATION FOR SEQ ID NO:X: (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTI (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  <10> <10> Skipped Sequences (NEW RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  <10> <10> Sequence id number <100> Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	)0
PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  8 Skipped Sequences (OLD RULES)	
Patentin ver. 2.0 "bug" in Patentin version 2.0 has caused the <2203-<2235 section to be missing from amino acid sequence(s)	/200n
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.  8 Skipped Sequences (OLD RULES)	CORP
to the subsequent amino acid sequence.  8 Skipped Sequences	
Skipped Sequences (OLD RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTIC (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  Skipped Sequences (NEW RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  (2) INFORMATION FOR SEQ ID NO:X: This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  (210> sequence id number  400> sequence id number  300  Use of n's or Xaa's (NEW RULES)  Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
(OLD RULES)  (2) INFORMATION FOR SEQ ID NO:X:  (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARAC	
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTIC (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  Skipped Sequences (NEW RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  (NEW RULES)  Use of n's or Xaa's  Use of n's and/or Xaa's have been detected in the Sequence Listing.  Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  Skipped Sequences (NEW RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  (NEW RULES)  Use of n's or Xaa's (NEW RULES)  Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	100"
This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  Skipped Sequences (NEW RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  (NEW RULES)  Use of n's or Xaa's  (NEW RULES)  Use of n's and/or Xaa's have been detected in the Sequence Listing.  Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	ics.)
Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).  Skipped Sequences (NEW RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.  400 > sequence id number 400 > sequence id number 000 Use of n's or Xaa's (NEW RULES)  Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220 > to <223 > is MANDATORY if n's or Xaa's are present.	
Skipped Sequences (NEW RULES)  Sequence(s) missing. If intentional, please use the following format for each skipped sequence.	
(NEW RULES)  <210> sequence id number <400> sequence id number 000 Use of n's or Xaa's (NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
Use of n's or Xaa's  (NEW RULES)  Use of a sequence id number  Use of n's and/or Xaa's have been detected in the Sequence Listing.  Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
Use of n's or Xaa's  (NEW RULES)  Use of n's and/or Xaa's have been detected in the Sequence Listing.  Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
(NEW RULES) Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
(NEW RULES)  Use of <220> to <223> is MANDATORY if n's or Xaa's are present.	
In <220> to <223> section, please explain location of $\bf n$ or $\bf Xaa$ , and $\bf which$ residue $\bf n$ or $\bf Xaa$ represents.	
11 Use of <213>Organism Sequence(s) are missing this mandatory field or its response.	
(NEW RULES)	
12 Use of <220>Feature Sequence(s) are missing the <220>Feature and associated headings.	
(NEW RULES)  Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"	
Please explain source of genetic material in <220> to <223> section.	
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new	v Rules)
13 Patentin ver. 2.0 "bug" Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted	

Instead, please use "File Manager" or any other means to copy file to floppy disk.

file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).

5. GUCKER

1647

RAW SEQUENCE LISTING DATE: 07/07/2000 PATENT APPLICATION: US/09/115,589 TIME: 09:34:34

Input Set : A:\Muscdaml.app

Output Set: N:\CRF3\07072000\1115589.raw

```
Does Not Comply
     3 <110> APPLICANT: Van Eyk, Jennifer E.
                                                                             Corrected Diskette Needed
             Iscoe, Steven D
             Simpson, Jeremy A
     7 <120> TITLE OF INVENTION: Methods of Diagnosing Muscle Damage
                                                                              pr 1-2
     9 <130> FILE REFERENCE: 1997-023-02US
    11 <140> CURRENT APPLICATION NUMBER: 09/115,589
     12 <141> CURRENT FILING DATE: 1998-07-15
    14 <150> PRIOR APPLICATION NUMBER: 60/052,697
    15 <151> PRIOR FILING DATE: 1997-07-16
    17 <160> NUMBER OF SEQ ID NOS: 18
    19 <170> SOFTWARE: PatentIn Ver. 2.1
    21 <210> SEQ ID NO: 1
    22 <211> LENGTH: 12
    23 <212> TYPE: PRT
    24 <213> ORGANISM: Unknown
    26 <220> FEATURE:
    27 <221> NAME/KEY: PEPTIDE
    28 <222> LOCATION: (1)..(12)
    29 <223> OTHER INFORMATION: Myosin light chain 1
    31 <220> FEATURE:
    32 <221> NAME/KEY: PEPTIDE
                                                           what about Xaa's at locationi / and ??
     33 <222> LOCATION: (7)
34 <223> OTHER INFORMATION: May be either Pro or Ala
36 <230 SEQUENCE: 1
W--> 37
Xaa Xaa Lys Lys Pro Glu Xaa Lys Ala Asp Asp Ala
5 10
    41 <210> SEQ ID NO: 2
    42 <211> LENGTH: 12
    43 <212> TYPE: PRT
    44 <213> ORGANISM: Unknown
    46 <220> FEATURE:
    47 <221> NAME/KEY: PEPTIDE
    48 <222> LOCATION: (1)..(12)
56 <210> SEQ ID NO: 3
    57 <211> LENGTH: 11
    58 <212> TYPE: PRT
    59 <213> ORGANISM: Unknown
    61 <220> FEATURE:
    62 <221> NAME/KEY: PEPTIDE
    63 <222> LOCATION: (1)..(11)
    64 <223> OTHER INFORMATION: malate dehydrogenase
                                                     iten 10
    66 <400> SEQUENCE: 3
W--> 67 Xaa Lys Val Ala Leu Gly Ala Xaa dly Gly Ile
```

```
RAW SEQUENCE LISTING
                                                                        DATE: 07/07/2000
                         PATENT APPLICATION: US/09/115,589
                                                                        TIME: 09:34:34
                          Input Set : A:\Muscdaml.app
                         Output Set: N:\CRF3\07072000\I115589.raw
      71 <210> SEQ ID NO: 4
      72 <211> LENGTH: 13
      73 <212> TYPE: PRT
      74 <213> ORGANISM: Unknown
      76 <220> FEATURE:
      77 <221> NAME/KEY: PEPTIDE
      78 <222> LOCATION: (1)..(13)
79 <2223 OTHER INFORMATION: ATP g synthase chain
81 <400> SEQUENCE: 4
W--> 88 Xaa Xaa Leu Lys Asp Ile Thr Arg Arg Leu Lys Ser Ile
                                                                              Hen 10
      86
      86 210> SEQ ID NO: 5
                                                      10
      87 <211> LENGTH: 10
      88 <212> TYPE: PRT
      89 <213> ORGANISM: Unknown
      91 <220> FEATURE:
      92 <221> NAME/KEY: PEPTIDE
      93 <222> LOCATION: (1)..(10)
94 <223 OTHER INFORMATION: ATP synthase oligomycin conferring protein 96 400> SEQUENCE: 5
W--> 97 Xaa Xaa Lys Leu Val Arg Pro Pro Val Gln
98 1 5 10
      101 <210> SEQ ID NO: 6
102 <211> LENGTH: 10
                                                                                                             RECEIVED
      103 <212> TYPE: PRT
      104 <213> ORGANISM: Unknown
      106 <220> FEATURE:
                                                                                                                 JUL 28 2000
      107 <221> NAME/KEY: PEPTIDE
      108 <222> LOCATION: (1)..(10)
      109 <223> OTHER INFORMATION: serum albumin
111 <400> SEQUENCE: 6
                                                                                                             TECH CENTER 1600/2900
W--> 11/2 Xaa Ala His Lys Ser Glu Ile Ala His Arg
           1
<210> SEQ ID NO: 7
      116
      117 <211> LENGTH: 11
      118 <212> TYPE: PRT
      119 <213> ORGANISM: Unknown
      121 <220> FEATURE:
      122 <221> NAME/KEY: PEPTIDE
      123 <222> LOCATION: (4)
      124 <223> OTHER INFORMATION: May be Arg or Leu
      126 <220> FEATURE:
      127 <221> NAME/KEY: PEPTIDE
      128 <222> LOCATION: (1)..(11)
129 <223> OTHER INFORMATION: triose phosphate isomerase
131 <40> SEQUENCE; 7
W--> 132 Xaa Pro Ser Xaa Lys Phe Phe Val Gly Gly Asn
133 10
```

RAW SEQUENCE LISTING DATE: 07/07/2000 PATENT APPLICATION: US/09/115,589 TIME: 09:34:34

Input Set : A:\Muscdaml.app

Output Set: N:\CRF3\07072000\I115589.raw

```
136 <210> SEQ ID NO: 8
  137 <211> LENGTH: 209
  138 <212> TYPE: PRT
  139 <213> ORGANISM: Unknown
  141 <220> FEATURE:
  142 <221> NAME/KEY: PEPTIDE
  143 <222> LOCATION: (1)..(209)
  144 <223> OTHER INFORMATION: Human cardiac troponin I
  146 <220> FEATURE:
  147 <223> OTHER INFORMATION: Swiss prot identification number P19429
  149 <300> PUBLICATION INFORMATION:
  150 <303> JOURNAL: FEBS Lett.
 151 <304> VOLUME: 270
152 <306> PAGES: 57-61
. 153 <307> DATE: 1990
 155 <400> SEQUENCE: 8
  156 Ala Asp Gly Ser Ser Asp Ala Ala Arg Glu Pro Arg Pro Ala Pro Ala 157 \phantom{-}1\phantom{+}5\phantom{+}5\phantom{+}1\phantom{+}1\phantom{+}1\phantom{+}1
 159 Pro Ile Arg Arg Arg Ser Ser Asn Tyr Arg Ala Tyr Ala Thr Glu Pro 160 20 25 30
 162 His Ala Lys Lys Lys Ser Lys Ile Ser Ala Ser Arg Lys Leu Gln Leu
163 35 40 45
 165 Lys Thr Leu Leu Gln Ile Ala Lys Gln Glu Leu Glu Arg Glu Ala
166 50 55 60
 168 Glu Glu Arg Arg Gly Glu Lys Gly Arg Ala Leu Ser Thr Arg Cys Gln
169 65 70 75 80
 171 Pro Leu Glu Leu Ala Gly Leu Gly Phe Ala Glu Leu Gln Asp Leu Cys 172 85 90 95
 174 Arg Gln Leu His Ala Arg Val Asp Lys Val Asp Glu Glu Arg Tyr Asp 175 \phantom{\bigg|}100\phantom{\bigg|}105\phantom{\bigg|}105\phantom{\bigg|}
 177 Ile Glu Ala Lys Val Thr Lys Asn Ile Thr Glu Ile Ala Asp Leu Thr
178 120 125
 180 Gln Lys Ile Phe Asp Leu Arg Gly Lys Phe Lys Arg Pro Thr Leu Arg 181 130 135 140
 183 Arg Val Arg Ile Ser Ala Asp Ala Met Met Gln Ala Leu Leu Gly Ala
184 145 150 155 160
 186 Arg Ala Lys Glu Ser Leu Asp Leu Arg Ala His Leu Lys Gln Val Lys
187 165 170 175
 189 Lys Glu Asp Thr Glu Lys Glu Asn Arg Glu Val Gly Asp Trp Arg Lys
190 185 190
 192 Asn Ile Asp Ala Leu Ser Gly Met Glu Gly Arg Lys Lys Lys Phe Glu
193 195 200 205
 195 Ser
 199 <210> SEQ ID NO: 9
 200 <211> LENGTH: 186
201 <212> TYPE: PRT
 202 <213> ORGANISM: Unknown
 204 <220> FEATURE:
 205 <221> NAME/KEY: PEPTIDE
```

RAW SEQUENCE LISTING DATE: 07/07/2000 PATENT APPLICATION: US/09/115,589 TIME: 09:34:35

Input Set : A:\Muscdaml.app

Output Set: N:\CRF3\07072000\I115589.raw

```
206 <222> LOCATION: (1)..(186)
    207 <223> OTHER INFORMATION: Human slow skeletal troponin I
    209 <220> FEATURE:
    210 <223> OTHER INFORMATION: Swiss prot identification number P19237
    212 <300> PUBLICATION INFORMATION:
    213 <303> JOURNAL: Genomics
    214 <304> VOLUME: 7
    215 <306> PAGES: 346-357
    216 <307> DATE: 1990
    218 <400> SEQUENCE: 9
   219 Pro Glu Val Glu Arg Lys Pro Lys Ile Thr Ala Ser Arg Lys Leu Leu
220 1 5 10 15
   222 Leu Lys Ser Leu Met Leu Ala Lys Ala Lys Glu Cys Trp Glu Gln Glu
223 20 25 30
   225 His Glu Glu Arg Glu Ala Glu Lys Val Arg Tyr Leu Ala Glu Arg Ile
226 35 40 45
   228 Pro Thr Leu Gln Thr Arg Gly Leu Ser Leu Ser Ala Leu Gln Asp Leu
229 50 60
   231 Cys Arg Glu Leu His Ala Lys Val Glu Val Val Asp Glu Glu Arg Tyr
232 65 70 75 80
   234 Asp Ile Glu Ala Lys Cys Leu His Asn Thr Arg Glu Ile Lys Asp Leu
235 90 95
   237 Lys Leu Lys Val Met Asp Leu Arg Gly Lys Phe Lys Arg Pro Pro Leu
238 100 105 110
   240 Arg Arg Val Arg Val Ser Ala Asp Ala Met Leu Arg Ala Leu Leu Gly
241 115 120 125
   243 Ser Lys His Lys Val Ser Met Asp Leu Arg Ala Asn Leu Lys Ser Val
244 130 135 140
   246 Lys Lys Glu Asp Thr Glu Lys Glu Arg Pro Val Glu Val Gly Asp Trp 247 145 150 150 155 160
   249 Arg Lys Asn Val Glu Ala Met Ser Gly Met Glu Gly Arg Lys Lys Met 250 165 170 175
   252 Phe Asp Ala Ala Lys Ser Pro Thr Ser Gln
   253
               180
   256 <210> SEQ ID NO: 10
   257 <211> LENGTH: 181
   258 <212> TYPE: PRT
   259 <213> ORGANISM: Unknown
   261 <220> FEATURE:
   262 <221> NAME/KEY: PEPTIDE
   263 <222> LOCATION: (1)..(181)
   264 <223> OTHER INFORMATION: Human fast skeletal troponin I
   266 <220> FEATURE:
   267 <223> OTHER INFORMATION: Swiss prot identification number P48788
   269 <300> PUBLICATION INFORMATION:
   270 <303> JOURNAL: Biochim. Biophys. Acta
   271 <304> VOLUME: 1217
' 272 <306> PAGES: 338-340
-> 273 <307> DATE: 1994
```

 RAW SEQUENCE LISTING
 DATE: 07/07/2000

 PATENT APPLICATION:
 US/09/115,589
 TIME: 09:34:35

Input Set : A:\Muscdaml.app

Output Set: N:\CRF3\07072000\I115589.raw

```
275 <400> SEQUENCE: 10
 276 Gly Asp Glu Glu Lys Arg Asn Arg Ala Ile Thr Ala Arg Arg Gln His
                                                10
 279 Leu Lys Ser Val Met Leu Gln Ile Ala Ala Thr Glu Leu Glu Lys Glu
280 20 25 30
 282 Glu Ser Arg Arg Glu Ala Glu Lys Gln Asn Tyr Leu Ala Glu His Cys
283 35 40 45
                35
 285 Pro Pro Leu His Ile Pro Gly Ser Met Ser Glu Val Gln Glu Leu Cys
286 50 55 60
 288 Lys Gln Leu His Ala Lys Ile Asp Ala Ala Glu Glu Glu Lys Tyr Asp
289 65 70 75 80
 291 Met Glu Val Arg Val Gln Lys Thr Ser Lys Glu Leu Glu Asp Met Asn
292 85 90 95
 294 Gln Lys Leu Phe Asp Leu Arg Gly Lys Phe Lys Arg Pro Pro Leu Arg 295 100 105 110
 297 Arg Val Arg Met Ser Ala Asp Ala Met Leu Lys Ala Leu Leu Gly Ser
298 115 120 125
 300 Lys His Lys Val Cys Met Asp Leu Arg Ala Asn Leu Lys Gln Val Lys 301 130 135 140
 303 Lys Glu Asp Thr Glu Lys Glu Arg Asp Leu Arg Asp Val Gly Asp Trp
304 145 150 155 160
 306 Arg Lys Asn Ile Glu Glu Lys Ser Gly Met Glu Gly Arg Lys Lys Met
307 165 170 175
 309 Phe Glu Ser Glu Ser
310 180
                180
 313 <210> SEQ ID NO: 11
  314 <211> LENGTH: 210
 315 <212> TYPE: PRT
316 <213> ORGANISM: Unknown
 318 <220> FEATURE:
 319 <221> NAME/KEY: PEPTIDE
 320 <222> LOCATION: (1)..(210)
 321 <223> OTHER INFORMATION: Rat cardiac troponin I
 323 <220> FEATURE:
 324 <223> OTHER INFORMATION: Swiss prot identification number P23693
  326 <300> PUBLICATION INFORMATION:
  327 <303> JOURNAL: Biochemistry
 328 <304> VOLUME: 30
. 329 <306> PAGES: 707-712
 330 <307> DATE: 1991
 332 <400> SEQUENCE: 11
 333 Ala Asp Glu Ser Ser Asp Ala Ala Gly Glu Pro Gln Pro Ala Pro Ala 334 1 5 10 15
 334 1
 336 Pro Val Arg Arg Arg Ser Ser Ala Asn Tyr Arg Ala Tyr Ala Thr Glu 337 \phantom{\bigg|}20\phantom{\bigg|}25\phantom{\bigg|}30\phantom{\bigg|}
 339 Pro His Ala Lys Lys Lys Ser Lys Ile Ser Ala Ser Arg Lys Leu Gln
 340 35
                          40
                                                           45
 342 Leu Lys Thr Leu Met Leu Gln Ile Ala Lys Gln Glu Met Glu Arg Glu
```

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/115,589

DATE: 07/07/2000 TIME: 09:34:36

Input Set : A:\Muscdaml.app

Output Set: N:\CRF3\07072000\I115589.raw

L:37 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 L:52 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 L:67 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 L:82 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 L:97 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 L:112 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 L:132 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 L:153 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY L:216 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY L:273 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD, MMM-YYYY or SEASON-YYYY, Wrong Journal Date: YYYY-MM-DD, MMM-YYYY or Season-YYYY L:330 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY L:393 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY L:504 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD, MMM-YYYY or SEASON-YYYY, Wrong Journal Date: YYYY-MM-DD, MMM-YYYY or Season-YYYY L:579 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY L:654 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY L:726 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY L:804 M:285 W: Invalid Journal Date: Wrong YYYY-MM-DD,MMM-YYYY or SEASON-YYYY, Wrong Journal Date:YYYY-MM-DD, MMM-YYYY or Season-YYYY